NCT07411222 Emotional Eating, Sleep Quality, Mental State and Metabolic Syndrome
| NCT ID | NCT07411222 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abant Izzet Baysal University |
| Condition | Schizophrenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 78 participants |
| Start Date | 2026-05-30 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 78 participants in total. It began in 2026-05-30 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In predominantly medication-naïve schizophrenic patients, those exhibiting partial metabolic disorders have significantly worse sleep quality and sleep onset time; poor sleep predicted metabolic dysregulation even after controlling for confounding factors. Mental health, sleep, and eating behavior interact in ways that strongly influence the risk of obesity and MetS. Emotional eating (eating in response to emotions rather than hunger) is central to this network and appears to be closely associated with psychiatric illnesses, particularly depression, anxiety, and sleep disorders. There is a continuing need to elucidate the frequency, level, and relationship of emotional eating with other factors in individuals with SMI. Therefore, this study aims to elucidate this complex relationship, thereby shedding light on new ways to reduce metabolic risks in psychiatric patients.
Eligibility Criteria
Inclusion Criteria: * Being registered with the Bolu İzzet Baysal Mental Health and Diseases Hospital Community Mental Health Center, * Having a severe chronic psychiatric illness (Schizophrenia Spectrum and Other Psychotic Disorders and Bipolar Disorder) followed by the Bolu İzzet Baysal Mental Health and Diseases Hospital Community Mental Health Center for at least 6 months, * Being in remission (Complete Remission (Pre-Remission): Symptoms remaining below threshold values for at least 2 months (8 weeks). A state of improvement lasting more than 2 months is generally referred to as "remission"), * Schizophrenia remission definition: 8 diagnostically significant symptoms were selected from the Positive and Negative Syndrome Scale. * Bipolar disorder remission definition: Complete remission is defined as the absence of acute attacks and the presence of minimal/very mild symptoms. * Being between 18-65 years of age, * Being able to understand what is read and give written consent. Exclusion Criteria: * Having a diagnosis of mental retardation, * Having other neurocognitive disorders, primarily dementia, according to DSM-V (as it can affect the ability to make decisions and give correct answers), * Not being able to speak or understand Turkish.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07411222 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07411222 currently recruiting?
Yes, NCT07411222 is actively recruiting participants. Contact the research team at melisa.bulut@ibu.edu.tr for enrollment information.
Where is the NCT07411222 trial being conducted?
This trial is being conducted at Bolu, Turkey (Türkiye).
Who is sponsoring the NCT07411222 clinical trial?
NCT07411222 is sponsored by Abant Izzet Baysal University. The trial plans to enroll 78 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.